"Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies" in Patent Application Approval Process (USPTO 20240109969).
In: Pharma Business Week, 2024-04-22, S. 1504-1504
serialPeriodical
Zugriff:
A patent application has been filed for a dosing regimen for therapies involving bispecific anti-EGFR/c-Met antibodies. These antibodies target epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met), which are both involved in cancer. The method involves administering the bispecific antibody at a dose of 1400-2100 mg once every 21 days. In some embodiments, a third-generation EGFR tyrosine kinase inhibitor (TKI) is also administered. The method may also include the use of chemotherapeutic agents such as pemetrexed and carboplatin. The patent application provides detailed information on the specific sequences and structures of the antibodies and compounds involved. [Extracted from the article]
Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies" in Patent Application Approval Process (USPTO 20240109969).
|
---|---|
Zeitschrift: | Pharma Business Week, 2024-04-22, S. 1504-1504 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6675 (print) |
Schlagwort: |
|
Sonstiges: |
|